Synovial inflammation in osteoarthritis progression

E Sanchez-Lopez, R Coras, A Torres… - Nature Reviews …, 2022 - nature.com
Osteoarthritis (OA) is a progressive degenerative disease resulting in joint deterioration.
Synovial inflammation is present in the OA joint and has been associated with radiographic …

[HTML][HTML] An update on the pathophysiology of osteoarthritis

A Mobasheri, M Batt - Annals of physical and rehabilitation medicine, 2016 - Elsevier
Introduction Osteoarthritis (OA) is one of the most common forms of arthritis. There is
accumulating evidence to suggest that OA is an inflammatory disease of the entire synovial …

2018 update of the EULAR recommendations for the management of hand osteoarthritis

M Kloppenburg, FPB Kroon, FJ Blanco… - Annals of the …, 2019 - ard.bmj.com
Since publication of the European League Against Rheumatism (EULAR) recommendations
for management of hand osteoarthritis (OA) in 2007 new evidence has emerged. The aim …

Erosive hand osteoarthritis: latest findings and outlook

M Favero, E Belluzzi, A Ortolan, M Lorenzin… - Nature Reviews …, 2022 - nature.com
Osteoarthritis (OA) most commonly affects knee joints, and the next most commonly affected
sites are the hands and hips. Three distinct hand OA phenotypes have been described …

Role of low-grade inflammation in osteoarthritis

CR Scanzello - Current opinion in rheumatology, 2017 - journals.lww.com
Role of low-grade inflammation in osteoarthritis : Current Opinion in Rheumatology Role of
low-grade inflammation in osteoarthritis : Current Opinion in Rheumatology Log in or Register …

Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management

M Marshall, FE Watt, TL Vincent… - Nature Reviews …, 2018 - nature.com
Osteoarthritis (OA) is a highly prevalent condition, and the hand is the most commonly
affected site. Patients with hand OA frequently report symptoms of pain, functional limitations …

A roadmap to target interleukin-6 in osteoarthritis

R Wiegertjes, FAJ van de Loo… - …, 2020 - academic.oup.com
Joint inflammation is present in the majority of OA patients and pro-inflammatory mediators,
such as IL-6, are actively involved in disease progression. Increased levels of IL-6 in serum …

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with …

M Kloppenburg, C Peterfy, IK Haugen… - Annals of the …, 2019 - ard.bmj.com
Objective To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the
anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in …

[HTML][HTML] A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis–the HUMOR trial

D Aitken, LL Laslett, F Pan, IK Haugen, P Otahal… - Osteoarthritis and …, 2018 - Elsevier
Objective To assess the efficacy of adalimumab in patients with erosive hand osteoarthritis
(OA). Method Patients> 50 years old, meeting the American College of Rheumatology (ACR) …

Methotrexate treatment in hand osteoarthritis refractory to usual treatments: a randomised, double-blind, placebo-controlled trial

S Ferrero, R Wittoek, E Allado, C Cruzel… - Seminars in arthritis and …, 2021 - Elsevier
Objective To examine the effect of methotrexate (MTX) on pain and structural progression in
symptomatic erosive hand osteoarthritis (HOA). Methods This 1-year prospective, single …